Replies to post #200841 on Cytodyn Inc (CYDY)

[Learning53]

Nader's good at thinking out of the box... I've never looked into "go fund me" type things, but there's a growing number of people out there that know about leronlimab or want to see it available - ask the Long Hauler's.

CytoDyn has not used all of its resources. If Nader truly wants to keep prices "REASONABLE" rather than BP style PRICES, we might be able to work deals with different interest groups.

CytoDyn is addressing the "plagues" of our time obviously including Covid, but beyond. I'm terming Cancer (in its innumerable forms) a plague of sorts, Stroke, NASH, and on and on.

If my family was prone to ABC disease and CytoDyn had the key... I've already purchased a share or two here because Leronlimab will address some of the issues that affect or will affect my family. I bet I'm not alone in that motivation.

Now Nader's a pretty busy guy, but there must be an expert in "crowd -funding" who could turn on the tap(s) by initiating mutually beneficial arrangements.

And there would be other significant benefits as well.

IMO

[Rockydoxie]

"The CYDY press releases for their NASH results come across like they're written by someone with no medical/statistical experience whatsoever. The PRs are vague to the extent that they are misleading (probably on purpose)".

"Madrigal attacking GALT makes no sense. Madrigal's drug is in Phase III for NASH compared to Belapectin which is in Phase III for NASH cirrhosis. Look at the protocols: different baseline values, and different primary endpoints. But here is a tip for the Madrigal pumpers, please go to the CYDY board, where the rogue CEO is misleading investors regarding their NASH data. The misled retail investors are anxiously awaiting the results of Leronlimab's 700 mg dose. They presented data on the 350 mg, and the way it was reported was highly suspect."

The above comments (in quotes) were from the GALT stock msg. board and happened to mention CYDY.

Can anyone make an unbiased comment on the above? I've owned GALT for years and they're in the NASH space (for cirrhosis) and the space is difficult for approval. I was always suspicious of CYDY w/ the NASH application as many companies have been in the space for a long time w/o successful (to date) results.

I'm a long holder of CYDY. This is my first post. I don't pump or bash.

TIA

[Learning53]

Except is there a 700 mg dosage report for TNBC? I actually was referring to NASH.

No excuse - confused - need some Leronlimab NOW!!!

IMO

***

(and since Leronlimab appears capable of crossing the blood-brain-barrier, it may be helpful addressing inflammatory stress in the brain. This is extremely relevant to SEVERAL neuro-degenerative conditions including AD, PD, etc.)

The idea that leronlimab addresses so many conditions means

When you take it for Covid-19, its effects may be also seen elsewhere in the various (human) systems beyond just those dealing with Covid. This phenomenon was noticed in the CD10 trial when the test group's impressive safety results (less SAEs or AEs with leronlimab vs. placebo) were noted. This is a provocative situation >> Leronlimab's side effects appear to be beneficial. WOW!

(this is IMPORTANT - so saying it again...)

This is a provocative situation >> Leronlimab's side effects appear to be beneficial, instead of detrimental. WOW!

I want a Leronlimab TUNE-UP!


now!

IMO

[StealthGold]

You are right NP could start selling lemonade on the corner to raise funds. Or sell cookies - who would resist NP/SK cookies?
You guys are just unreal!